LINK Strengthens Presence in Switzerland with Distribution Agreement
News Sep 04, 2015
LINK has announced the appointment of a new distributor in Switzerland - Chemie Brunschwig AG. This is LINK's first formal partnership in Europe, and an important part of its strategy to strengthen Company representation in important market segments, thus increasing access to LINK's range of innovative reagents for oligo therapeutics and diagnostics.
Chemie Brunschwig AG distributes over one million different chemicals, life science products and lab-ware to laboratories ranging from research and development to production in the Swiss market. Founded in 1948, the company has developed a wide R&D user base across industry, hospitals, private and public health labs, research centres, and universities. Located in Basle, on the border to Germany and France in the Bio Valley, staff are able to communicate with customers in all three regional languages.
Emmanuel Picard, Marketing & Sales Manager for Chemie Brunschwig, commented: "We are delighted to agree this partnership with LINK. It is an exciting opportunity to expand our portfolio of products, whilst playing a key role in driving LINK's growth in the region."
Dr David Ricketts, CEO of LINK, added: "In our home market of Europe, there are certain geographical areas where our customers can benefit from increased local representation due to factors such as language and purchasing regulations. It is essential therefore that we give these customers such a service. We have already developed a successful working relationship with Chemie Brunschwig, driving growth in Switzerland, and formally appointing them as our distributor was the next logical step. They are a company very much aligned to our ethos of quality and service, and we look forward to working with them to take our business forward."
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE
Infection Blood Test of Limited Value in Reducing Antibiotic UseNews
Overall antibiotic use was not curbed by giving physicians the results of biomarker tests in patients with suspected lower respiratory tract infections, according to findings from the Procalcitonin Antibiotic Consensus Trial (ProACT).READ MORE
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.